HARVARD PILGRIM HEALTH CARE INSTITUTE Boston, MA—With a significantly costlier medication for HIV preexposure prophylaxis (PrEP) approved in 2019, a new study examined reasons patients switched to the new drug. Study results indicate that a minority of those who switched had a documented clinical reason to do so. The study was led by researchers at Harvard Medical...